Source: DGNews  |  Posted 9 years ago

By W. A. Thomasson
Special to DG News

CHICAGO, IL -- October 4, 2002 -- When quality of life is considered, combined estrogen-progestin hormone therapy (HT) is highly cost-effective for treatment of perimenopausal symptoms.

The finding emerges from a study presented here October 3 at the annual meeting of the North American Menopause Society (NAMS).

The poster, presented by Marc F. Botteman, MSc, of Herqules, Abt Clinical Trials in Bethesda, MD, and colleagues there and at Pfizer Pharmaceuticals, also concluded that the lower cost of the femhrt